Researchers launched CombiCoR‑Vax, a phase II trial testing a sequential immunotherapy‑then‑chemotherapy regimen in patients with refractory microsatellite‑stable (MSS) metastatic colorectal cancer (mCRC). The trial targets a population historically unresponsive to immune checkpoint blockade and employs combination scheduling to prime and then debulk tumor burden. Investigators aim to evaluate safety, response rates, and translational biomarkers that might predict benefit in MSS disease. If successful, the sequential design could offer a pathway to convert immunotherapy‑resistant tumors into more treatable states and inform future combination strategies.